A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Clinical trial NCT00585195 · COMPLETED

Trial details

NCT number: NCT00585195
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer ALK-positive Non-Small Cell Lung Cancer c-Met Dependent Non-Small Cell Lung Cancer ROS Marker Positive Systemic Anaplastic Large-Cell Lymphoma Advanced Malignancies Except Leukemia

Start date: 2006-04-19
Primary completion: 2020-07-30
Enrollment: 596

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.